Information Provided By: 
Fly News Breaks for April 17, 2017
VLRX
Apr 17, 2017 | 06:07 EDT
Cowen analyst Doug Schenkel initiated Valeritas with an Outperform saying its revamped commercial strategy under a different management structure has yielded promising early results. The analyst believes Valeritas has a differentiated insulin pump specifically for Type 2 patients within a $2-3B+ US TAM, and at a $100MM enterprise value, there could be material upside if management executes relative to expectations in 2017 and beyond.
News For VLRX From the Last 2 Days
There are no results for your query VLRX
